# FcRH5 (FCRL5)

Source: https://onco.cc/targets/fcrh5/  
OnCo record `fcrh5` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FcRH5 is a surface protein found almost only on B cells and myeloma plasma cells, which makes it a target for T-cell engaging antibodies in multiple myeloma.

## Summary

FCRL5 encodes Fc receptor-like 5, a B-lineage surface receptor expressed on mature B cells and retained on plasma cells; on myeloma cells expression is near-universal and higher than on normal counterparts, in part through 1q21 gain where the gene sits. Cevostamab, a FcRH5 x CD3 bispecific antibody, is in late-stage trials for relapsed and refractory multiple myeloma; no approval names the antigen yet.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: FcRH5; FCRH5; IRTA2; CD307e; Fc receptor-like 5
- Tags: biomarker-parent; surface-antigen
- Symbol: FCRL5
- Class: surface-antigen
- Biology: A type I transmembrane protein with immunoglobulin-like domains that modulates B-cell receptor signalling; its restricted lineage expression, like BCMA and GPRC5D, is what makes it a T-cell redirection target.
- Where found: Multiple myeloma (near-universal on plasma cells); B-cell lymphomas and chronic lymphocytic leukaemia

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/FCRL5
- HGNC HGNC:18508: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18508
- UniProt Q96RD9: https://www.uniprot.org/uniprotkb/Q96RD9/entry

## Connected records

- biomarkers: [FcRH5 expression](https://onco.cc/biomarkers/fcrh5-expression/)
- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [Cevostamab](https://onco.cc/drugs/cevostamab/)

---
JSON: https://onco.cc/api/v1/entities/fcrh5.json